Blackstone, Taisho Pharma said to be among final bidders for Takeda's Japan OTC unit

Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical’s consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.